Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics. CA Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Network TCGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7.

Article  Google Scholar 

Horst D, Chen J, Morikawa T, Ogino S, Kirchner T, Shivdasani RA. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res. 2012;72:1547–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Migrating cancer stem cells — an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005;5:744–9.

Article  CAS  PubMed  Google Scholar 

Vermeulen L, De Sousa E Melo F, Van Der Heijden M, Cameron K, De Jong JH, Borovski T, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12:468–76.

Article  CAS  PubMed  Google Scholar 

Tsao LC, Force J, Hartman ZC. Mechanisms of therapeutic antitumor monoclonal antibodies. Cancer Res. 2021;81:4641–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17.

Article  PubMed  PubMed Central  Google Scholar 

Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86:10024.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, Mardi A, Aghebati-Maleki A, Aghebati-Maleki L, et al. The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. Front Immunol. 2023;14:1113882.

Article  PubMed  PubMed Central  Google Scholar 

Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, et al. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci USA. 1997;94:469–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garin-Chesa P, Sakamoto J, Welt S, Real FX, Rettig WJ, Old LJ, et al. Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. Int J Oncol. 1996;9:465–71.

CAS  Google Scholar 

Welt S, Ritter G, Williams C, Cohen LS, John M, Jungbluth A, et al. Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res. 2003;

Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, et al. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res. 2005;11:4818–26.

Article  CAS  PubMed  Google Scholar 

Infante JR, Bendell JC, Goff LW, Jones SF, Chan E, Sudo T, et al. Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer. Eur J Cancer. 2013;49:1169–75.

Article  CAS  PubMed  Google Scholar 

Bendell JC, Lenz HJ, Ryan T, El-Rayes BF, Marshall JL, Modiano MR, et al. Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Invest New Drugs. 2014;32:682–90.

Article  CAS  PubMed  Google Scholar 

Uhlitz F, Bischoff P, Peidli S, Sieber A, Trinks A, Luethen M, et al. Mitogen-activated protein kinase activity drives cell trajectories in colorectal cancer. EMBO Mol Med. 2021;13:e14123.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stancikova J, Krausova M, Kolar M, Fafilek B, Svec J, Sedlacek R, et al. NKD1 marks intestinal and liver tumors linked to aberrant Wnt signaling. Cell Signal. 2015;27:245–56.

Article  CAS  PubMed  Google Scholar 

Qu X, Sandmann T, Frierson H, Fu L, Fuentes E, Walter K, et al. Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter. Oncogene. 2016;35:6403–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang N, Zhang R, Zou K, Yu W, Guo W, Gao Y, et al. Keratin 23 promotes telomerase reverse transcriptase expression and human colorectal cancer growth. Cell Death Dis. 2017;8:e2961.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kumar A, Priyamvada S, Ge Y, Jayawardena D, Singhal M, Anbazhagan AN, et al. A novel role of SLC26A3 in the maintenance of intestinal epithelial barrier integrity. Gastroenterology. 2021;160:1240–55.e3.

Article  CAS  PubMed  Google Scholar 

Zhang D, Huang H, Zheng T, Zhang L, Cui B, Liu Y, et al. Polymeric immunoglobulin receptor suppresses colorectal cancer through the AKT-FOXO3/4 axis by downregulating LAMB3 expression. Front Oncol. 2022;12:924988.

Article  CAS  PubMed  Google Scholar 

Mooney SM, Rajagopalan K, Williams BH, Zeng Y, Christudass CS, Li Y, et al. Creatine kinase brain overexpression protects colorectal cells from various metabolic and non-metabolic stresses. J Cell Biochem. 2011;112:1066–75.

Article  CAS  PubMed  Google Scholar 

Wood SM, Gill AJ, Brodsky AS, Lu S, Friedman K, Karashchuk G, et al. Fatty acid binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon γ pathway. Mod Pathol. 2017;30:123.

Article  CAS  PubMed  Google Scholar 

Johnstone CN, White SJ, Tebbutt NC, Clay FJ, Ernst M, Biggs WH, et al. Analysis of the regulation of the A33 antigen gene reveals intestine-specific mechanisms of gene expression. J Biol Chem. 2002;277:34531–9.

Article  CAS  PubMed  Google Scholar 

Rageul J, Mottier S, Jarry A, Shah Y, Théoleyre S, Masson D, et al. KLF4-dependent, PPARγ-induced expression of GPA33 in colon cancer cell lines. Int J Cancer. 2009;125:2802–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rader C, Ritter G, Nathan S, Elia M, Gout I, Jungbluth AA, et al. The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. J Biol Chem. 2000;275:13668–76.

Article  CAS  PubMed  Google Scholar 

Moore PA, Shah K, Yang Y, Alderson R, Roberts P, Long V, et al. Development of MGD007, a gpA33 x CD3-bispecific DART protein for T-cell immunotherapy of metastatic colorectal cancer. Mol Cancer Ther. 2018;17:1761–72.

Article  CAS  PubMed  Google Scholar 

Tomé-Amat J, Herrero-Galán E, Oñaderra M, Martínez-del-Pozo Á, Gavilanes JG, Lacadena J. Preparation of an engineered safer immunotoxin against colon carcinoma based on the ribotoxin hirsutellin A. FEBS J. 2015;282:2131–41.

Article  PubMed  Google Scholar 

Sanz L, Ibáñez-Pérez R, Guerrero-Ochoa P, Lacadena J, Anel A. Antibody-based immunotoxins for colorectal cancer therapy. Biomedicines. 2021;9:1729.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Narbona J, Gordo RG, Tomé-Amat J, Lacadena J. A new optimized version of a colorectal cancer-targeted immunotoxin based on a non-immunogenic variant of the ribotoxin α-Sarcin. Cancers. 2023;15:1114.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Membreno R, Cook BE, Fung K, Lewis JS, Zeglis BM. Click-mediated pretargeted radioimmunotherapy of colorectal carcinoma. Mol Pharm. 2018;15:1729–34.

Article